- Pfizer acquires Rinat Neuroscience
- Pfizer to acquire Idun Pharmaceuticals in cash transaction
- Elan, AHP, Tel Aviv Univ. develop Alzheimer's drugs
- Pfizer buys Bioren for an undisclosed sum
- Pfizer and Medarex enter long-term MAb agreement
- Pfizer acquires Esperion Therapeutics for $1.25bn
- Pfizer to help develop and market Eisai's Alzheimer's drug
- Pfizer buys Angiosyn in deal based largely on milestones
- Merck & Co. buys Aton Pharma
- Pfizer buys Vicuron for $1.9bn in cash
- Genentech exercises option from Rinat for RI 624; backs out
- Vanda Pharmaceuticals nets $55.4mm from IPO
- Targacept nets $41.85mm in IPO
- AstraZeneca takes on Targacept's cognitive disorder candidate; deal ends
- Rinat Neuroscience closes $40mm Series B round
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.